BLCO
Medical Instruments & Supplies · Healthcare
Chairman
2023-03-06–present
Chairman
Bausch & Lomb Corp (BLCO)Equibles does not estimate personal net worth.
Get an email with a short summary when Bausch & Lomb Corp publishes a filing, an earnings call transcript or a press release.
Get BLCO alertsBrent Saunders is recorded as Chairman at Bausch & Lomb Corp (BLCO) since March 6, 2023. Bausch & Lomb Corp reported in an 8-K filed October 13, 2026 that Brent Saunders resigned as member of the Company's board of directors, effective October 12, 2026. Bausch & Lomb Corp reported in an 8-K filed October 13, 2026 that Brent Saunders resigned as Chief Executive Officer, effective October 12, 2026. Bausch & Lomb Corp reported in an 8-K filed February 15, 2023 that Brent Saunders was appointed Chair of the Board, effective March 6, 2023. Equibles holds 5 filed executive changes naming Brent Saunders; each is listed under recent activity with its source filing. Brent Saunders has spoken on 11 earnings calls across 1 company, most recently for Bausch & Lomb Corp on July 29, 2026. Bausch & Lomb Corp is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at Bausch & Lomb Corp includes Thomas J. Appio (CEO and Board Member), Thomas W. Ross, Sr. (Chairman and Board Member), Sam Eldessouky (CFO) and 7 others.
“In connection with his departure, Mr. Saunders will also cease serving on the Board, effective as of the Separation Date.”
“Brent Saunders, Chief Executive Officer of the Company and a member of the Company's board of directors (the "Board"), and the Board have mutually agreed that Mr. Saunders will depart from the Company, effective as of October 12, 2026 (the "Separation Date").”
“Thank you, George, and thanks to everyone joining us today, especially my colleagues around the world whose commitment and passion are at the heart of everything we achieve.”
“Thanks, George, and good morning, good afternoon, and good evening to everyone joining us today, including my colleagues from around the world. Before we get into the quarter, I want to address the question we hear most from investors.”
“I'm going to start by highlighting Q4 and full-year results, which show we don't just talk about strategy, we execute it. Sam will put more context around our performance and provide 2026 guidance, and Andrew will cover opportunities to expand our leadership in dry eye.”
“I'm going to put our first quarter performance in context and provide updates on two timely topics, followed by Sam's focus on the financials, including 2025 guidance.”
“I'm going to show progress against our strategy through the lens of our fourth quarter and full year results, and Sam will go deeper on our performance and provide 2025 guidance.”
2023-03-06–present
2023-03-06–2026-10-12
Start not stated–2026-10-12
BLCO
Medical Instruments & Supplies · Healthcare
Chairman
2023-03-06–present